<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594308</url>
  </required_header>
  <id_info>
    <org_study_id>0705-20 IUCRO-0196</org_study_id>
    <nct_id>NCT00594308</nct_id>
  </id_info>
  <brief_title>In-Vivo Activated T-Cell Depletion to Prevent GVHD</brief_title>
  <official_title>In-Vivo Activated T-Cell Depletion to Prevent GVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects (good and bad) of the medication
      basiliximab in combination with cyclosporine with cyclosporine alone for the prevention of
      graft-versus-host disease.

      This research is being done because there is no completely safe and effective prevention for
      graft-versus-host disease. It is known that cyclosporine helps with GVHD but we would like to
      know if the addition of basiliximab will decrease the incidence and/or severity of GVHD after
      a transplant known as nonmyeloablative (&quot;mini&quot; transplant).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Treatment ineffective
  </why_stopped>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Acute Grade II-IV GVHD</measure>
    <time_frame>until 30 days after stem cell transplant</time_frame>
    <description>Number of patients with Grade II-IV GVHD according to NMDP/CIBMTR GVHD severity scale. This scale measures the degree of GVHD involvement in the patient's skin (inflammatory skin disease), liver (bilirubin levels) and intestinal tract (amount of diarrhea) as well as the level of decline in a patient's activity and physical abilities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).</measure>
    <time_frame>until 30 days after stem cell transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days for Absolute Neutrophil Count to Recover</measure>
    <time_frame>From Day -1 (day before stem cell infusion) to Day+20 (20 days after stem cell infusion)</time_frame>
    <description>Average number of day per patient for absolute neutrophil count to recover(&gt; 500/mm3 for 3 consecutive days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Cytopenias: Platelet Transfusion Independence</measure>
    <time_frame>From Day -1 (day before stem cell infusion) to Day +20 (20 days after stem cell infusion)</time_frame>
    <description>Average number of days per patient for resolution of cytopenias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.</measure>
    <time_frame>up to 2 years after stem cell transplant</time_frame>
    <description>Number of patients who died due to transplant related toxicities</description>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <condition>Mantle-Cell Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelofibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60mg/kg/day for two consecutive days (-7,-6).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25mg/m2/day for 5 consecutive days</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>1000 mg will be administered through day +60 and then discontinued if there is no GVHD.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myelogenous leukemia, Acute lymphocytic leukemia, Chronic myelogenous leukemia,
             Chronic lymphocytic leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Mantle cell,
             Hodgkin's Disease, Multiple Myeloma, Myelofibrosis with disease-specific eligibility
             requirements as outlined in the protocol

          -  Donor Requirement: Must have a fully HLA-matched (10 of 10) related or unrelated
             donor, eighteen years of age or older, who is capable of undergoing GCSF mobilization
             and apheresis.

        Exclusion Criteria:

          -  Active CNS disease (the presence of leukemic blasts in the CSF)

          -  Pregnancy or breast-feeding

          -  SGOT &gt;3x upper limit of normal

          -  Creatinine &gt;2 or creatinine clearance &lt;50cc/hr.

          -  Fractional shortening by echocardiogram not within normal limits per institution

          -  Pulmonary function: DLCO less that 50% of normal predicted, corrected for anemia

          -  Prior allogeneic transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Universtiy School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Universtiy Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>August 5, 2011</results_first_submitted>
  <results_first_submitted_qc>March 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2012</results_first_posted>
  <last_update_submitted>September 26, 2014</last_update_submitted>
  <last_update_submitted_qc>September 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Basiliximab 20 mg</title>
          <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basiliximab 20 mg</title>
          <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.80" spread="11.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Acute Grade II-IV GVHD</title>
        <description>Number of patients with Grade II-IV GVHD according to NMDP/CIBMTR GVHD severity scale. This scale measures the degree of GVHD involvement in the patient's skin (inflammatory skin disease), liver (bilirubin levels) and intestinal tract (amount of diarrhea) as well as the level of decline in a patient's activity and physical abilities.</description>
        <time_frame>until 30 days after stem cell transplant</time_frame>
        <population>All patient that received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Basiliximab 20 mg</title>
            <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Grade II-IV GVHD</title>
          <description>Number of patients with Grade II-IV GVHD according to NMDP/CIBMTR GVHD severity scale. This scale measures the degree of GVHD involvement in the patient's skin (inflammatory skin disease), liver (bilirubin levels) and intestinal tract (amount of diarrhea) as well as the level of decline in a patient's activity and physical abilities.</description>
          <population>All patient that received study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).</title>
        <time_frame>until 30 days after stem cell transplant</time_frame>
        <population>ITT population. All patient that received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Basiliximab 20 mg</title>
            <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).</title>
          <population>ITT population. All patient that received study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days for Absolute Neutrophil Count to Recover</title>
        <description>Average number of day per patient for absolute neutrophil count to recover(&gt; 500/mm3 for 3 consecutive days).</description>
        <time_frame>From Day -1 (day before stem cell infusion) to Day+20 (20 days after stem cell infusion)</time_frame>
        <population>ITT: All patient that received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Basiliximab 20 mg</title>
            <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days for Absolute Neutrophil Count to Recover</title>
          <description>Average number of day per patient for absolute neutrophil count to recover(&gt; 500/mm3 for 3 consecutive days).</description>
          <population>ITT: All patient that received study drug</population>
          <units>days per patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Cytopenias: Platelet Transfusion Independence</title>
        <description>Average number of days per patient for resolution of cytopenias.</description>
        <time_frame>From Day -1 (day before stem cell infusion) to Day +20 (20 days after stem cell infusion)</time_frame>
        <population>IIT: All patients that received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Basiliximab 20 mg</title>
            <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Cytopenias: Platelet Transfusion Independence</title>
          <description>Average number of days per patient for resolution of cytopenias.</description>
          <population>IIT: All patients that received study drug.</population>
          <units>days per patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.33" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.</title>
        <description>Number of patients who died due to transplant related toxicities</description>
        <time_frame>up to 2 years after stem cell transplant</time_frame>
        <population>Intent To Treat: All patients that received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Basiliximab 20 mg</title>
            <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.</title>
          <description>Number of patients who died due to transplant related toxicities</description>
          <population>Intent To Treat: All patients that received study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Basiliximab 20 mg</title>
          <description>All patients that received Basiliximab 20 mg monoclonal therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>GvHD</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GvHD</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Four patients experienced grade 3-4 GVHD and this study was stopped.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Nelson, MD</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317-278-6871</phone>
      <email>ronelson@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

